AOTI is dedicated to providing Advanced Wound Care products that utilize our patented non-invasive Topical Wound Oxygen (two₂™) therapy.  Our innovative two₂™ products can help close all wound types, including; Chronic (diabetic, pressure and venous ulcers) and Acute (post surgical, cosmetic and burn) wounds.

two₂™ therapy is unique in that it addresses the fundamental reasons wounds do not close, by reversing the tissue hypoxia and stimulating the underlying cellular mechanisms needed for tissue to regenerate, utilizing a environment that destroys unwanted pathogens and helps combat infection.

In closing previously unresponsive wounds and all wound faster, two₂™ therapy will have significant impact in reducing overall healthcare costs and greatly improving the quality of life of patients. 

The worldwide Advanced Wound Care market segment potential is estimated to be in excess of $40 billion annually and is currently less then 3% penetrated.¹

The Global Wound Care Market

Wound care is one of the most rapidly expanding medical device market segments for both manufacturers and providers. Recent worldwide industry reports estimate the market will exceed $11.8 billion by 2009.² 

The wound care market is also one of the most costly components of the United States health care system. Market data estimates that more than 89 million patients are treated annually for all wound conditions at costs in excess of $25 billion.³ 

In the USA the number of surgeries performed in ambulatory surgical centers increased 191% between 1990 and 2000, while the average length of hospital stay decreased from 6.4 days in 1990 to 4.6 days in 2003, indicating a need for products that accelerate wound healing.  Also, the growing acceptance of cosmetic surgery, with a total US market of $6.3 billion in 2004 is forecast to increase 11.2% through 2007, presents an increased demand for accelerated wound healing and scar inhibition products.⁴

Advanced Wounds need Advanced Wound Care

It is estimated that there is currently more than 20 million advanced wound patients worldwide that could be treated with our unique two₂™ therapy. With limited existing active therapeutic choices, this market segment alone already exceeds $4.1 billion per year. ^1,2

As the world population continues to age, demand for advanced wound care products will increase to treat chronic wounds such as pressure ulcers, venous stasis ulcers, and diabetic ulcers.  In the USA alone there are more than six million chronic wounds involving various types of skin ulcers that are difficult and expensive to treat.³

There are 2.5 million Americans with venous leg ulcers⁹; and more than 3 million have pressure ulcers. Pressure ulcers alone add an estimated burden of an additional 2.2 million Medicare hospital days at a cost of treatment that ranges anywhere from $2,000 to $40,000 per ulcer. Studies indicate that LOS for patients who develop pressure ulcers while in the hospital is 2 to 5 times the typical LOS for patients who don’t develop pressure ulcers while in the hospital.^2,3,5,6,10

The majority of chronic wounds occur in people over age 65. By the year 2030, the US population over age 65 will increase from 13% to 20%.⁵

The incidences of diabetes are forecast to increase 165%, affecting up to 29 million people in the United States alone by 2050. Of the 16 million Americans who have diabetes already, 15% to 20% will develop a diabetic foot ulcer, resulting in 2 million diabetic foot ulcers cases annually.⁷

Over 10 million people in the US age 60 and above are diagnosed with diabetes, which represents over 20% of this age group. Diabetes associated wounds or ulcers are a chronic complication of this disease, and in the worst scenario result in amputations. In 2002 there were approximately 82,000 non-traumatic lower limb amputations performed in the US, directly associated with diabetes.⁸ Worldwide there is a diabetic related amputation being performed every 30 seconds.¹

The total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. It is currently ranked as the fifth leading cause of death in the US.⁸  33% of the US population is obese or morbidly obese, and we all know the links associated to obesity and diabetes.³

References::

1. Interview with Catherine Burzik, KCI, Jim Cramer's "Mad Money" CNBC, May 25, 2007
2. Nerac, Inc. WOUND MARKET LANDSCAPE, MARCH 28, 2007
3. CMS Website
4. MedTech Insight Feb 2004
5. Task Force on the Future of the Health Care Labor Force in a “Graying Society.” Who will care for each of us? Chicago, Ill: Nursing Institute University of Illinois 2001
5. Advanced Wound Care Biologics: World Market Analysis, Theta Reports,2002
6. Strategic Analysis of Global Wound Care Markets, Frost and Sullivan, 2002
7. Lipsky BA, Pecoraro RD, Wheat JL. The diabetic foot. Soft tissue and bone infection. Infect Dis Clin Noth Am. 1990;4:409–432.
8. American Diabetes Association website
9. Kerstein MD, Gahtan V. Outcomes of venous ulcer care: results of a longitudinal study. Ostomy Wound Manage. 2000; 46(6):22–29.
10. Krasner D. Prevalence of chronic non-healing wounds. In: Rodeheaver G, Krasner DL. Chronic Wound Care: A Clinical Source Book for Professionals. King of Prussia, Pa: Health Management Publications, Inc: 1990:14.